Japan Tissue Engineering (7774) · TargetSoftened
Proof of Jack's Cost-Effectiveness
First written in FY2017-Q2. 1 of 2 entries say "Softened", first in FY2018. Latest entry: FY2018.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
JACK cost-effectiveness assessment and reflection in reimbursement pricingA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2018SoftenedAnnual report
「Jack was selected as a product for the cost-effectiveness assessment introduced on a pilot basis by the Ministry of Health, Labour and Welfare. However, comparison with symptomatic treatment (drug therapy) was deemed difficult to analyse, so no price adjustment was made and there was no change to its reimbursement price.」
The disclosure states that demonstrating cost-effectiveness through comparison with symptomatic treatment was deemed difficult to analyse and did not lead to a price adjustment. - FY2017-Q2First statedAnnual report
「We will demonstrate Jack's cost-effectiveness using a comparison of its costs with those of symptomatic treatment and efficacy assessment data from post-marketing use-results surveys.」
For Jack, which was selected for the pilot cost-effectiveness assessment, this is the first indication of a goal to demonstrate cost-effectiveness using a cost comparison with symptomatic treatment and use-results survey data.